-
Chapter
Definition, Nomenclature, and Diagnostic Criteria
The term Raynaud’s phenomenon (RP) is unusual within the pantheon of medical eponyms in that it describes a symptom complex rather than a distinct medical syndrome in its own right. This state of affairs can b...
-
Chapter
Managing Complicated Digital Ulcers
Short title: Managing complex SSc-DU
-
Chapter
Clinical Outcome Measures in Raynaud’s Phenomenon
Raynaud’s phenomenon (RP) is a major cause of morbidity, resulting in pain, numbness, impaired hand function, emotional distress, decreased social participation, isolation and reduced health-related quality of...
-
Article
Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey
This study aimed to assess the incidence, predictors, and outcomes of breakthrough infection (BI) following coronavirus disease (COVID-19) vaccination in patients with systemic sclerosis (SSc), a risk group as...
-
Chapter
Vaccinations in Patients with Systemic Sclerosis
The autoimmune rheumatic diseases (ARDs) are associated with higher rates of serious infection caused by the dysregulated immune responses inherent within the diseases themselves and the widespread use of immu...
-
Article
Delayed adverse events following COVID-19 vaccination in patients with systemic sclerosis and other autoimmune diseases: a substudy of the COVAD-2 cohort
Data on short-term safety of COVID-19 vaccination in patients with systemic sclerosis (SSc) were explored previously in the first COVID-19 vaccination in autoimmune diseases (COVAD) survey conducted in 2021. H...
-
Article
Open AccessLong-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (A...
-
Article
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumat...
-
Article
Open AccessCOVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (...
-
Article
Open AccessIMproving PULmonary hypertension Screening by Echocardiography: IMPULSE
The world symposium on pulmonary hypertension (PH) has proposed that PH be defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg as assessed by right heart catheterisation (RHC). Transthoracic echocardi...
-
Article
The clinical relevance of Raynaud’s phenomenon symptom characteristics in systemic sclerosis
Raynaud’s phenomenon (RP) is a cardinal feature of systemic sclerosis (SSc) and manifests with pain, digital colour change, sensory symptoms, and impaired function. SSc-RP is exacerbated by cold exposure (RP ‘...
-
Article
Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders
Antiphospholipid syndrome (APS) is an acquired, autoimmune thrombophilia that can occur as a primary disorder (with no associated disease) or secondary to infection, medication usage and autoimmune rheumatic d...
-
Article
Author Correction: Raynaud phenomenon and digital ulcers in systemic sclerosis
A Correction to this paper has been published: https://doi.org/10.1038/s41584-021-00591-5.
-
Article
How do patients define Raynaud’s phenomenon? Differences between primary and secondary disease
To examine how people define Raynaud’s phenomenon (RP) based on their lived experiences and explore if differences exist depending on primary or secondary RP diagnosis.
-
Article
Correction to: How do patients define Raynaud’s phenomenon? Differences between primary and secondary disease
A correction to this paper has been published: 10.1007/s10067-021-05620-y
-
Chapter
Raynaud’s Phenomenon
Raynaud’s phenomenon is typically the earliest clinical manifestation of systemic sclerosis and is a major cause of disease-related morbidity. The clinical features of Raynaud’s phenomenon are caused by digita...
-
Article
Open AccessThe promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis
A myositis-specific autoantibody can now be identified in the majority of patients with myositis. They identify homogeneous patient subgroups and are key tools in develo** a personalized approach to disease ...
-
Article
Raynaud phenomenon and digital ulcers in systemic sclerosis
Raynaud phenomenon is a symptom complex caused by impaired digital perfusion and can occur as a primary phenomenon or secondary to a wide range of underlying causes. Raynaud phenomenon occurs in virtually all ...
-
Article
Raynaud’s phenomenon—an update on diagnosis, classification and management
Raynaud’s phenomenon (RP) is used to describe a symptom complex caused by digital vascular compromise. RP is a clinical diagnosis. The typically episodic nature of RP has resulted in a reliance upon patient se...
-
Article
Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice?
Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc). We audited adherence with available recommendations regarding cardiopulmonary screening for PAH in S...
